About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:3850439
Allelic
Composition
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53tm1Brn
Genetic
Background
involves: 129P2/OlaHsd * 129S7/SvEvBrd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2atm1.1Brn mutation (2 available); any Cdkn2a mutation (29 available)
Nf2tm2Gth mutation (3 available); any Nf2 mutation (55 available)
Trp53tm1Brn mutation (6 available); any Trp53 mutation (145 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
muscle

nervous system

mortality/aging
• following adenoviral cre treatment, median survival time is 80 days

neoplasm
• following adenoviral cre treatment, 100% of mice develop highly invasive thoracic tumors (including malignant mesotheliomas, 47 of 51; rhabdomyosarcomas, 4 of 51; and schwannomas, 1 of 51)
• following adenoviral cre treatment, 75% of mice develop of aggressive malignant mesotheliomas at a shorter latency than in mice carrying other combinations of Cdkn2atm2Brn, Nf2tm2Gth, and Trp53tm1Brn alleles
• following adenoviral cre treatment, 75% of mice develop of aggressive malignant mesotheliomas at a shorter latency than in mice carrying other combinations of Cdkn2atm2Brn, Nf2tm2Gth, and Trp53tm1Brn alleles

Mouse Models of Human Disease
OMIM ID Ref(s)
Mesothelioma, Malignant; MESOM 156240 J:132943


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
06/15/2016
MGI 6.04
The Jackson Laboratory